Cancer Monoclonal Antibodies Market: By Application (Breast Cancer, Blood Cancer, Liver Cancer, Brain cancer, Colorectal Cancer, Other), By Type of Antibody (Murine Antibodies, Humanized Antibodies, Chimeric Antibodies), By Conjugation (Immunocytokines, Immunoliposome, Radioimmunotherapy, Antibody Directed Enzyme Prodrug Therapy(ADEPT)), By Distribution Channel (Hospital Pharmacies, Retail Pharmacie, Online Pharmacies) and By Geography.

Purchase Option

$ 4400
$ 6600
$ 8900

Cancer Monoclonal Antibodies Market size was valued at USD 47.2 billion and is expected to grow at a CAGR of 11.8% from 2023-2029. A monoclonal antibody drug in cancer treatments engages natural immune system functions to fight cancer. Cancer monoclonal antibodies may be used in combination with other cancer treatments. An antibody attaches itself to a specific molecule (antigen) on the surface of a cancer cell when the antibody binds to an antigen, it acts as a flag to attract disease-fighting molecules or as a trigger that promotes the destruction of cancer cells by another immune system process. Due to its specificity, monoclonal antibodies have the least adverse effects than other cancer-treating drugs. Currently cancer monoclonal antibodies market is witnessing significant growth. Targeted and combination therapy drugs are leading in the market. Several market players collaborating to develop antibody drugs to treat various types of cancers. In January 2017, AbCellera Biologics, Inc. collaborated with Pfizer Inc. for a new therapeutic antibody discovery. AbCellera will use its monoclonal antibody (mAb) screening techniques in the discovery of function-modulating antibodies against undisclosed membrane protein targets. Academic institutions and organizations like the National Institute of Health (USA), the National Cancer Institute (USA), and many others are collaborating and participating in cancer research and awareness activities.

Cancer Monoclonal Antibodies Market Key Developments:

In May 2017, the U.S. Food and Drug Administration (FDA) granted accelerated approval to AstraZeneca's durvalumab (IMFINZI) for the treatment of patients with locally advanced or metastatic urothelial carcinoma In 2016, U.S Food and Drug Administration (FDA) approved Genentech Oncology's tecentriq (atezolizumab) for the treatment of patients with metastatic non-small cell lung cancer.

 

Global Cancer Monoclonal Antibodies Market Summary

Study Period

2024-2030

Base Year

2023

CAGR

11.8%

Largest Market

North America

Fastest Growing Market

Asia Pacific
Cancer Monoclonal Antibodies Market Dynamics

The market growth of cancer monoclonal antibodies is driven by increased prevalence of cancer worldwide. According to WHO, cancer is one of the leading cause of deaths worldwide. In 2012, there were around 14 Mn new cases of cancer, 8.2 Mn people died because of cancer and numbers of new cancer cases are projected to rise 70% in coming decades. In addition, monoclonal antibodies are proved to be having less adverse effects when compared to conventional non-targeted therapies. Increasing investment in the development of monoclonal antibodies, technological advancements that enabling the genetic sequencing and increasing specificity of the antibodies are fueling the sales revenue ofcancer monoclonal antibodies market. However, the high cost of development, stringent regulatory guidelines, long period of clinical trials, are some of the factors hinder growth of cancer monoclonal antibodies market.

Global Cancer Monoclonal Antibodies Market Segmentation

By Application
  • Breast Cancer
  • Blood Cancer
  • Liver Cancer
  • Brain cancer
  • Colorectal Cancer
  • Others
By Type of Antibody
  • Murine Antibodies
  • Humanized Antibodies
  • Chimeric Antibodies
By Conjugation
  • Immunocytokines
  • Immunoliposome
  • Radioimmunotherapy
  • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
By Distribution channel
  • Hospital Pharmacies
  • Retail Pharmacies
  • Online Pharmacies

Frequently Asked Questions

The cancer monoclonal antibodies market is projected to expand at a CAGR of 11.8% during the forecast period

Merck & Co. Inc. (U.S.), F. Hoffmann-La Roche AG (Switzerland), Spectrum Pharmaceuticals (U.S.), Eli Lilly and Company (U.S.), Amgen Inc. (U.S.), Bristol-Meyer Squibb (U.S.), Sanofi  (France)

North America is the fastest-growing region for cancer monoclonal antibodies market

Key Features of the Reports

  • The report provides granular level information about the market size, regional market share, historic market (2019-2023), and forecast (2024-2030)
  • The report covers in-detail insights about the competitor's overview, company share analysis, key market developments, and their key strategies
  • The report outlines drivers, restraints, unmet needs, and trends that are currently affecting the market
  • The report tracks recent innovations, key developments, and start-up details that are actively working in the market
  • The report provides a plethora of information about market entry strategies, regulatory framework, and reimbursement scenario
  1. Executive summary
  2. Global Cancer Monoclonal Antibodies Market Introduction
    • Global Cancer Monoclonal Antibodies Market - Taxonomy
    • Global Cancer Monoclonal Antibodies Market -Definitions
      • Application
      • Distribution Channel
  1. Global Cancer Monoclonal Antibodies Market Dynamics
    • Drivers
    • Restraints
    • Opportunities/Unmet Needs of the Market
    • Trends
    • Global Cancer Monoclonal Antibodies Market Dynamics - Factors Impact Analysis
    • Global Cancer Monoclonal Antibodies Market - Regulations
      • US
      • Europe
      • Japan
    • Global Cancer Monoclonal Antibodies Market - Recent Product Launches
  2. Global Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
    • Year-over-Year (Y-o-Y) Growth Analysis (%)
    • Market Oppurtunity Analysis
  3. Global Cancer Monoclonal Antibodies Market, By Application, 2018 - 2022 and Forecast, 2023 - 2029
    • Breast Cancer
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Blood Cancer
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Liver Cancer
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Brain cancer
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Colorectal Cancer
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Others
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Type of Antibody, 2018 - 2022 and Forecast, 2023 - 2029
    • Murine Antibodies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Humanized Antibodies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Chimeric Antibodies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Conjugation, 2018 - 2022 and Forecast, 2023 - 2029
    • Immunocytokines
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Immunoliposome
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Radioimmunotherapy
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Distribution Channel, 2018 - 2022 and Forecast, 2023 - 2029
    • Hospital Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Retail Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Online Pharmacies
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
  1. Global Cancer Monoclonal Antibodies Market Forecast, By Region, 2018 - 2022 and Forecast, 2023 - 2029
    • North America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Europe
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Asia-Pacific
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Latin America
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Middle East and Africa
      • Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029 (Revenue, USD Mn)
      • Year-over-Year (Y-o-Y) Growth Analysis (%) and Market Share Analysis (%)
      • Market Opportunity Analysis
    • Global Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Region, 2023 - 2029
  2. North America Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn) Y-o-Y Growth (%) and Market Share (%)
      • US
      • Canada
    • North America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2023 - 2029
    • North America Cancer Monoclonal Antibodies Market Dynamics - Trends
  3. Europe Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Germany
      • UK
      • France
      • Spain
      • Italy
      • Russia
      • Poland
      • Rest of Europe
    • Europe Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2023 - 2029
    • Europe Cancer Monoclonal Antibodies Market Dynamics - Trends
  4. Asia-Pacific Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn),
  5. Y-o-Y Growth (%), and Market Share (%)
    • Japan
    • China
    • India
    • ASEAN
    • Australia & New Zealand
    • Rest of Asia-Pacific
  • Asia-Pacific Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2023 - 2029
  • Asia-Pacific Cancer Monoclonal Antibodies Market Dynamics - Trends
  1. Latin America Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Brazil
      • Mexico
      • Argentina
      • Venezuela
      • Rest of Latin America
    • Latin America Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2023 - 2029
    • Latin America Cancer Monoclonal Antibodies Market Dynamics - Trends
  2. Middle East & Africa Cancer Monoclonal Antibodies Market Analysis, 2018 - 2022 and Forecast, 2023 - 2029
    • Application Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Breast Cancer
      • Blood Cancer
      • Liver Cancer
      • Brain cancer
      • Colorectal Cancer
      • Others
    • Antibody Type Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Murine Antibodies
      • Humanized Antibodies
      • Chimeric Antibodies
    • Conjugation Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Immunocytokines
      • Immunoliposome
      • Radioimmunotherapy
      • Antibody Directed Enzyme Prodrug Therapy(ADEPT)
    • Distribution Channel Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%) and Market Share (%)
      • Hospital Pharmacies
      • Retail Pharmacies
      • Online Pharmacies
    • Country Analysis (2018 - 2022) and Forecast (2023 - 2029) by Revenue (USD Mn), Y-o-Y Growth (%), and Market Share (%)
      • Gulf Cooperation Council (GCC) Countries
      • Israel
      • South Africa
      • Rest of MEA
    • MEA Cancer Monoclonal Antibodies Market- Opportunity Analysis Index - By Application, By Antibody Type, By Conjugation, By Distribution Channel, and Country, 2023 - 2029
    • MEA Cancer Monoclonal Antibodies Market Dynamics - Trends
  3. Competition Landscape
    • Strategic Dashboard of Top Market Players
    • Company Profiles (Introduction, Financial Analysis, Drug & Service Offerings, Key Developments, Strategies, and SWOT Analysis)
      • Merck & Co. Inc. (U.S.)
      • Hoffmann-La Roche AG (Switzerland)
      • Spectrum Pharmaceuticals (U.S.)
      • Eli Lilly and Company (U.S.)
      • Amgen Inc. (U.S.)
      • Bristol-Meyer Squibb (U.S.)
      • Sanofi (France)
      • AstraZeneca (U.K.)
  4. Research Methodology
  5. Key Assumptions and Acronyms
  • Merck & Co. Inc. (U.S.)
  • F. Hoffmann-La Roche AG (Switzerland)
  • Spectrum Pharmaceuticals (U.S.)
  • Eli Lilly and Company (U.S.)
  • Amgen Inc. (U.S.)
  • Bristol-Meyer Squibb (U.S.)
  • Sanofi  (France)
  • AstraZeneca (U.K.)

Adjacent Markets